Algorithmiq, Cleveland Clinic and IBM win $2m in Wellcome Leap quantum health challenge

A collaboration led by quantum start‑up Algorithmiq, with Cleveland Clinic and IBM, has won a $2 million prize in the first Quantum for Bio (Q4Bio) challenge, an initiative backed by Wellcome Leap to speed quantum approaches for healthcare. The award, announced on April 16, 2026, recognises work demonstrating scalable quantum algorithms with direct relevance to human health.

Launched in 2023, Q4Bio set out to identify, develop and demonstrate quantum algorithms for medical applications that could run on near‑term quantum computers expected over the next three to five years. Twelve international research teams received access to a combined $40 million in funding at the start of the programme; by March 2026, the field had narrowed to six Phase III finalists.

To qualify for a $2 million Phase III award, teams were required to show algorithms using more than 50 qubits and circuit depths on the order of 1,000 to 10,000 gates, along with a clear path to scaling. Meeting those thresholds pushed groups to work on today’s most capable hardware.

Five of the six Phase III finalists used IBM quantum computers to generate their results, underscoring the role of 100‑plus‑qubit “utility‑scale” systems in tackling demanding problems at the intersection of quantum information science and healthcare. The winning project focused on photodynamic therapy, a cancer treatment based on light‑activated drugs.

Algorithmiq developed an end‑to‑end hybrid quantum‑classical framework—combining methods for active space selection, state preparation, measurement and post‑processing—to run large‑scale molecular electronic structure simulations on IBM’s quantum processors.

By executing circuits for ground‑ and excited‑state experiments on up to 100 qubits, the team outlined a scalable route toward applying quantum computing to drug discovery and development. “This work provides one of the clearest indications to date that quantum computing can begin to impact real, chemically relevant problems, rather than simplified benchmarks,” said Sabrina Maniscalco, Algorithmiq’s CEO and co‑founder.

Across the finalist cohort, projects spanned drug discovery, genomics, biomarkers and fundamental biochemistry, each selecting a healthcare‑driven question that could be executed at significant scale on current quantum devices with potential to expand further.

Wellcome Leap, which funds high‑risk, high‑reward global health research with the aim of compressing timelines to five to ten years, positioned Q4Bio to offer an early look at how quantum computing may begin to support research in healthcare and the life sciences as more capable machines come online.